Nothing Special   »   [go: up one dir, main page]

NO2499161T3 - - Google Patents

Info

Publication number
NO2499161T3
NO2499161T3 NO10778877A NO10778877A NO2499161T3 NO 2499161 T3 NO2499161 T3 NO 2499161T3 NO 10778877 A NO10778877 A NO 10778877A NO 10778877 A NO10778877 A NO 10778877A NO 2499161 T3 NO2499161 T3 NO 2499161T3
Authority
NO
Norway
Application number
NO10778877A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09014136A external-priority patent/EP2322555A1/en
Application filed filed Critical
Publication of NO2499161T3 publication Critical patent/NO2499161T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
NO10778877A 2009-11-11 2010-11-11 NO2499161T3 (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US26020209P 2009-11-11 2009-11-11
EP09014136A EP2322555A1 (en) 2009-11-11 2009-11-11 Antibodies specific for claudin 6 (CLDN6)
US36161810P 2010-07-06 2010-07-06
EP10006956 2010-07-06
EP10778877.0A EP2499161B8 (en) 2009-11-11 2010-11-11 Antibodies specific for claudin 6 (CLDN6)
PCT/EP2010/006888 WO2011057788A1 (en) 2009-11-11 2010-11-11 Antibodies specific for claudin 6 (cldn6)

Publications (1)

Publication Number Publication Date
NO2499161T3 true NO2499161T3 (no) 2018-02-03

Family

ID=43480734

Family Applications (1)

Application Number Title Priority Date Filing Date
NO10778877A NO2499161T3 (no) 2009-11-11 2010-11-11

Country Status (29)

Country Link
US (5) US9487584B2 (no)
EP (4) EP4461354A3 (no)
JP (3) JP5889196B2 (no)
KR (4) KR102317098B1 (no)
CN (4) CN105348389B (no)
AU (3) AU2010318316B2 (no)
BR (1) BR112012011143B1 (no)
CA (2) CA2775373C (no)
CY (2) CY1120300T1 (no)
DK (2) DK3305813T3 (no)
ES (3) ES2784483T3 (no)
HR (2) HRP20171749T1 (no)
HU (2) HUE049404T2 (no)
IL (2) IL218628B (no)
LT (2) LT2499161T (no)
ME (1) ME02943B (no)
MX (3) MX347150B (no)
NO (1) NO2499161T3 (no)
NZ (2) NZ716587A (no)
PL (3) PL3689911T3 (no)
PT (2) PT2499161T (no)
RS (2) RS56502B1 (no)
RU (1) RU2675997C2 (no)
SG (2) SG10202110692WA (no)
SI (2) SI2499161T1 (no)
SM (1) SMT201700566T1 (no)
UA (2) UA128302C2 (no)
WO (1) WO2011057788A1 (no)
ZA (1) ZA201202418B (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358588A (ja) * 1986-08-29 1988-03-14 Toshiba Corp バ−コ−ド読取装置
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2010215700B2 (en) 2009-02-20 2015-11-19 Astellas Pharma Inc. Methods and compositions for diagnosis and treatment of cancer
CN105348389B (zh) 2009-11-11 2019-12-20 加尼梅德药物公司 密蛋白6(cldn6)特异性的抗体
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
NZ706004A (en) * 2011-05-13 2016-12-23 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
KR102128027B1 (ko) * 2011-05-13 2020-06-30 가니메드 파마슈티칼스 게엠베하 클라우딘 6을 발현하는 암 치료용 항체
CN103320381B (zh) * 2012-03-23 2015-04-15 上海市儿童医院 一种多能干细胞表面标志物及其用途
MY181648A (en) 2012-08-24 2020-12-30 Univ California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
EP2920209B1 (en) * 2012-11-13 2020-08-05 BioNTech SE Agents for treatment of claudin expressing cancer diseases
SG11201503593UA (en) 2012-11-13 2015-06-29 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
EP3738611A1 (en) * 2013-07-31 2020-11-18 BioNTech AG Diagnosis and therapy of cancer involving cancer stem cells
SG11201603397QA (en) * 2013-11-06 2016-05-30 Stemcentrx Inc Novel anti-claudin antibodies and methods of use
KR102813659B1 (ko) 2013-11-11 2025-05-28 추가이 세이야쿠 가부시키가이샤 개변된 항체 가변영역을 포함하는 항원 결합 분자
HUE050355T2 (hu) * 2014-04-01 2020-12-28 Biontech Cell & Gene Therapies Gmbh Claudin-6-specifikus immunreceptorok és T-sejt-epitópok
MA40921A (fr) * 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
TWI880146B (zh) 2014-11-11 2025-04-11 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
US10882906B2 (en) 2016-12-07 2021-01-05 Osaka University Claudin 5 antibody, and medicine containing said antibody
KR102667026B1 (ko) 2017-05-08 2024-05-20 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 항 cldn-5 항체, 및 그 항체를 함유하는 의약
WO2019048040A1 (en) * 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
CN116999573A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体－药物偶联物及其制造方法、药物组合物及其在制备治疗肿瘤的药物中的应用
EP3720963A4 (en) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha ANTIGEN BINDING MOLECULE INCLUDING A VARIABLE REGION OF MODIFIED ANTIBODIES BINDING TO CD3 AND CD137
JP2021510064A (ja) * 2018-01-05 2021-04-15 中外製薬株式会社 細胞傷害誘導治療剤
WO2020075325A1 (ja) * 2018-10-09 2020-04-16 公立大学法人福島県立医科大学 子宮体癌患者の予後予測バイオマーカー
CN113767113B (zh) * 2019-02-15 2025-01-03 因特格尔莫来库乐有限公司 密封蛋白6抗体及其用途
FI3941946T3 (fi) 2019-03-20 2025-03-28 Univ California Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja
KR20210143237A (ko) 2019-03-25 2021-11-26 다이이찌 산쿄 가부시키가이샤 항체-피롤로벤조디아제핀 유도체 컨쥬게이트
MX2022000111A (es) * 2019-07-10 2022-02-10 Chugai Pharmaceutical Co Ltd Moleculas de union a claudina-6 y usos de las mismas.
CN111087465B (zh) * 2019-12-24 2020-12-08 广州医科大学 一种针对密蛋白6的抗体偶联药物及应用
TW202235442A (zh) 2020-03-31 2022-09-16 日商中外製藥股份有限公司 密連蛋白6靶向多特異性抗原結合分子及其用途
WO2022183502A1 (zh) * 2021-03-05 2022-09-09 上海吉倍生物技术有限公司 抗cldn6抗体及其用途
WO2022192403A1 (en) * 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
WO2023053282A1 (ja) 2021-09-29 2023-04-06 中外製薬株式会社 がんの治療に用いるための細胞傷害誘導治療剤
KR20250046264A (ko) * 2022-07-29 2025-04-02 레전드 바이오테크 아일랜드 리미티드 클라우딘6 겹합 모이어티 및 이의 용도
EP4566633A1 (en) 2022-10-31 2025-06-11 Astellas Pharma, Inc. Antibody-drug complex containing toll-like receptor 7/8 dual agonist compound
TW202430574A (zh) 2022-11-30 2024-08-01 美商積分分子股份有限公司 針對密連蛋白６之抗體，包括其雙特異性格式
CN116064622B (zh) * 2023-02-13 2023-10-13 优睿赛思(武汉)生物科技有限公司 Claudin6-mCherry报告基因CHO-K1稳转细胞株制备及应用
WO2024235175A1 (zh) * 2023-05-12 2024-11-21 智泽童康(广州)生物科技有限公司 抗cldn6抗体及其用途
WO2024243561A1 (en) 2023-05-25 2024-11-28 The Regents Of The University Of California Methods of treating cancer
CN119371534B (zh) * 2024-08-21 2025-05-27 百吉生物医药(广州)股份有限公司 一种紧密连接蛋白抗体e02及其应用
CN119320451B (zh) * 2024-08-21 2025-05-16 百吉生物医药(广州)股份有限公司 一种紧密连接蛋白抗体d03及其应用
CN118754987B (zh) * 2024-08-21 2025-02-11 广州百吉生物制药有限公司 一种紧密连接蛋白抗体h04及其应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO2002008288A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5928631A (en) 1997-06-09 1999-07-27 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US20020127584A1 (en) 1997-09-18 2002-09-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
US6830894B1 (en) 1998-11-03 2004-12-14 Adherex Technologies, Inc. Compounds and methods for modulating claudin-mediated functions
CA2362423A1 (en) 1998-12-17 2000-06-22 Human Genome Sciences, Inc. 47 human secreted proteins
EP1155126A2 (en) 1999-02-22 2001-11-21 Incyte Pharmaceuticals, Inc. Genes associated with diseases of the colon
EP1185648B1 (en) 1999-06-02 2007-03-21 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
KR20080075044A (ko) * 1999-07-12 2008-08-13 제넨테크, 인크. Ｃｄ20에 결합하는 길항제를 사용한 외래 항원에 대한 면역반응 차단 방법
WO2001053312A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001051513A2 (en) 2000-01-14 2001-07-19 Corixa Corporation Ovarian tumor-associated sequences
DE60140676D1 (de) 2000-03-30 2010-01-14 Massachusetts Inst Technology Mediatoren von rns-interferenz, die rns-sequenzspezifisch sind
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004506413A (ja) 2000-06-23 2004-03-04 ジェネンテック・インコーポレーテッド 血管形成に関与する疾患の診断と治療のための組成物と方法
CA2416538A1 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU8470301A (en) 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP2005500034A (ja) * 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
EP2000545B1 (en) 2001-06-20 2011-08-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of lung tumor
CA2379661A1 (en) * 2002-03-28 2003-09-28 Kursad Turksen Paracellular drug delivery system
EP2011886A3 (en) 2002-04-16 2009-02-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1594447A2 (en) 2002-10-02 2005-11-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
NZ568769A (en) 2002-10-17 2010-04-30 Genmab As Human monoclonal antibodies against CD20
CA2503043A1 (en) 2002-10-18 2004-07-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
WO2005005601A2 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006033664A1 (en) 2004-03-08 2006-03-30 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
ITRM20050297A1 (it) * 2005-06-08 2006-12-09 Univ Siena Anticorpi diretti contro la proteina basica della mielina che riconoscono un epitopo del cd64 e uso di essi come immunodepressivi.
EP2520588A1 (en) 2005-08-19 2012-11-07 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
KR20170123712A (ko) * 2006-10-02 2017-11-08 메다렉스, 엘.엘.시. Ｃｘｃｒ4에 결합하는 인간 항체 및 이의 용도
BRPI0718644A2 (pt) * 2006-11-13 2013-11-26 Arius Res Inc Anticorpo monoclonal isolado, anticorpos humanizado e quimérico do anticorpo monoclonal isolado, linha de célula hibridoma isolada, método para iniciar a citotoxidez induzida por anticorpo de células cancerosas em uma amostra de tecido selecionada de um tumor humano, cdmab do anticorpo monoclonal isolado ou seu cdmab e usos de um anticorpo monoclonal ou seu cdmab, sozinho ou em conjução com pelo menos um agente quimioterapêutico, e composição
WO2008114733A1 (ja) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2009025759A1 (en) * 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
WO2009028663A1 (ja) 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
BRPI0907237A2 (pt) * 2008-01-11 2015-07-14 Univ Tokyo Anticorpo anti-cldn6
EP2285392A4 (en) 2008-04-11 2012-06-06 Bionovo Inc PROCEDURE AGAINST CANCER WITH EXTRACTS FROM GLEDITSIA SINENSIS LAM
EP2352764B1 (en) 2008-10-14 2018-03-28 Ablynx N.V. AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
DE102009026966A1 (de) 2008-12-18 2010-07-01 Robert Bosch Gmbh Betrieb eines Bremskraftverstärkers als Pedalsimulator
AU2010215700B2 (en) 2009-02-20 2015-11-19 Astellas Pharma Inc. Methods and compositions for diagnosis and treatment of cancer
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
CN105348389B (zh) 2009-11-11 2019-12-20 加尼梅德药物公司 密蛋白6(cldn6)特异性的抗体
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
NZ706004A (en) * 2011-05-13 2016-12-23 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
EP2605017A1 (de) 2011-12-16 2013-06-19 Protagen AG Markersequenzen für gynäkologisches Malignom und deren Verwendung
CN104703999A (zh) 2012-07-19 2015-06-10 安姆根有限公司 人btnl3蛋白、核酸和抗体及其用途
SG11201503593UA (en) * 2012-11-13 2015-06-29 Biontech Ag Agents for treatment of claudin expressing cancer diseases
HUE050355T2 (hu) * 2014-04-01 2020-12-28 Biontech Cell & Gene Therapies Gmbh Claudin-6-specifikus immunreceptorok és T-sejt-epitópok

Also Published As

Publication number Publication date
MX347150B (es) 2017-04-17
CN106432500B (zh) 2020-06-02
JP5889196B2 (ja) 2016-03-22
EP4461354A3 (en) 2025-03-19
CN102741289A (zh) 2012-10-17
JP2017140041A (ja) 2017-08-17
LT3305813T (lt) 2020-05-11
EP3305813B1 (en) 2020-01-15
KR102317098B1 (ko) 2021-10-25
PL2499161T3 (pl) 2018-03-30
SI2499161T1 (sl) 2017-12-29
HUE035516T2 (en) 2018-05-28
MX2012005444A (es) 2012-06-19
NZ716587A (en) 2017-10-27
UA117799C2 (uk) 2018-10-10
UA128302C2 (uk) 2024-06-05
MX385874B (es) 2025-03-18
EP3689911A1 (en) 2020-08-05
AU2018201640A1 (en) 2018-04-05
CN111875703A (zh) 2020-11-03
CY1123192T1 (el) 2021-10-29
KR101960509B1 (ko) 2019-03-20
JP6502992B2 (ja) 2019-04-17
DK3305813T3 (da) 2020-04-20
EP3689911B1 (en) 2024-08-21
HRP20200591T1 (hr) 2020-07-10
KR20120115226A (ko) 2012-10-17
US9932401B2 (en) 2018-04-03
EP2499161B1 (en) 2017-09-06
CN105348389A (zh) 2016-02-24
JP6125604B2 (ja) 2017-05-10
MX2020011790A (es) 2020-11-24
ES2784483T3 (es) 2020-09-28
SG10202110692WA (en) 2021-12-30
WO2011057788A1 (en) 2011-05-19
DK2499161T3 (da) 2017-11-27
CA2775373A1 (en) 2011-05-19
US20200339677A1 (en) 2020-10-29
EP3689911C0 (en) 2024-08-21
ES2988907T3 (es) 2024-11-22
IL218628A0 (en) 2012-05-31
SG10201500975YA (en) 2015-04-29
AU2018201640B2 (en) 2020-04-30
EP3305813A1 (en) 2018-04-11
KR102126964B1 (ko) 2020-06-25
PL3305813T3 (pl) 2021-04-19
CA2775373C (en) 2019-10-29
CN111875703B (zh) 2024-06-04
PT2499161T (pt) 2017-12-05
EP2499161A1 (en) 2012-09-19
HK1253300A1 (en) 2019-06-14
KR20210130250A (ko) 2021-10-29
HRP20171749T1 (hr) 2018-01-26
IL246710B (en) 2020-05-31
SI3305813T1 (sl) 2020-07-31
AU2010318316A1 (en) 2012-04-26
ZA201202418B (en) 2013-06-26
HUE049404T2 (hu) 2020-09-28
AU2010318316B2 (en) 2016-01-14
JP2013510808A (ja) 2013-03-28
US20180162938A1 (en) 2018-06-14
ES2649389T3 (es) 2018-01-11
IL246710A0 (en) 2016-08-31
US20160222125A1 (en) 2016-08-04
CY1120300T1 (el) 2019-07-10
ME02943B (me) 2018-10-20
US20240092896A1 (en) 2024-03-21
RS60168B1 (sr) 2020-05-29
PT3305813T (pt) 2020-04-22
BR112012011143A2 (pt) 2016-11-29
RS56502B1 (sr) 2018-02-28
US10745477B2 (en) 2020-08-18
EP4461354A2 (en) 2024-11-13
KR20200075903A (ko) 2020-06-26
LT2499161T (lt) 2017-11-27
US11858988B2 (en) 2024-01-02
PL3689911T3 (pl) 2024-11-18
CN102741289B (zh) 2016-08-03
EP2499161B8 (en) 2017-10-25
CN106432500A (zh) 2017-02-22
CN105348389B (zh) 2019-12-20
RU2675997C2 (ru) 2018-12-25
RU2012123995A (ru) 2013-12-20
BR112012011143B1 (pt) 2020-05-19
IL218628B (en) 2018-12-31
US20120308478A1 (en) 2012-12-06
AU2016202235B2 (en) 2017-12-07
US9487584B2 (en) 2016-11-08
KR20190031335A (ko) 2019-03-25
JP2016047845A (ja) 2016-04-07
CA3050655A1 (en) 2011-05-19
NZ734307A (en) 2020-05-29
SMT201700566T1 (it) 2018-01-11

Similar Documents

Publication Publication Date Title
BE2015C040I2 (no)
BRPI0925311A2 (no)
BR112012003062A2 (no)
BRPI0924307A2 (no)
BR112012000607A2 (no)
BR112012003080A2 (no)
NO2499161T3 (no)
BR122017024704A2 (no)
BR112012003853A2 (no)
BRPI0924534A2 (no)
BR112012001263A2 (no)
BR122019005883A2 (no)
BR112012002627A2 (no)
BR112012014856A2 (no)
BRPI1004942A2 (no)
BR112012000159A2 (no)
BR112012000255A2 (no)
BR112012000156A2 (no)
BRPI0924617A2 (no)
BR122017013721A2 (no)
BRPI0925022A2 (no)
BR112012000689A2 (no)
BR112012003654A2 (no)
BRPI0925016A2 (no)
BRPI0924020A2 (no)